Echinacea preparations are among the top-selling herbal supplements in Ireland, Europe, and North America, purchased by millions each autumn and winter in the hope of warding off or shortening the common cold. The evidence, however, is considerably more complicated than marketing suggests — a story of mixed trial results, species confusion, and genuine scientific debate.
Echinacea is a genus of flowering plants in the daisy family, native to North America. Three species are used medicinally: Echinacea purpurea, E. angustifolia, and E. pallida. Different parts of the plant — roots, aerial parts (leaves and flowers), or combinations — are used in different preparations. This diversity of species and plant parts is one reason the research literature is so difficult to interpret: "echinacea" on a label could refer to any of several quite different preparations with different active compound profiles.
The proposed active compounds include alkylamides, polysaccharides, caffeic acid derivatives (including echinacoside and chicoric acid), and glycoproteins. These are thought to modulate immune function, particularly stimulating macrophage and natural killer cell activity.
The Cochrane Collaboration has reviewed echinacea for the prevention and treatment of the common cold multiple times. The most recent comprehensive Cochrane review (Karsch-Völk et al. 2015) examined 24 randomised trials. The headline findings were:
A key challenge highlighted repeatedly in the Cochrane review is the lack of standardisation across products. A well-made E. purpurea aerial part preparation may perform differently from a root-based E. angustifolia extract or a combined multi-species formula. Comparing results across trials is therefore problematic.
The most positive recent trial data comes from a 2015 study in the journal Evidence-Based Complementary and Alternative Medicine (Raus et al.) and a 2012 multicentre trial (Jawad et al. in Evidence-Based Complementary and Alternative Medicine), both showing statistically significant reductions in cold incidence and duration with specific E. purpurea preparations. However, effect sizes were modest.
| Claim | Evidence Level | Source |
|---|---|---|
| Echinacea reduces cold incidence (prevention) | Limited / Mixed | Cochrane review 2015 (Karsch-Völk et al.) |
| Echinacea shortens cold duration | Limited / Mixed | Cochrane review 2015; some positive RCTs |
| E. purpurea aerial parts more evidence than root | Moderate (comparative) | Multiple studies; product heterogeneity issue |
| Echinacea stimulates immune markers (in vitro) | Moderate (lab) | Multiple in vitro studies |
| Echinacea shortens cold duration by one full day | Limited | Meta-analyses: modest effect at best, not consistent |
If you choose to try echinacea, the following considerations may improve your odds of using a preparation with at least some evidence behind it:
Allergy: Echinacea is in the Asteraceae (composite/daisy) family. People with allergies to ragweed, chrysanthemums, marigolds, chamomile, or other composites may have cross-reactive allergic responses to echinacea. Anaphylaxis to echinacea has been documented. If you have known composite plant allergies, discuss with your GP before using echinacea.
Autoimmune conditions: Echinacea is an immune stimulant. People with autoimmune conditions — rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease — should use echinacea with caution, as theoretically stimulating the immune system could worsen these conditions. Consult your GP or specialist before use.
Immunosuppressant medication: For the same reason, echinacea should not be combined with immunosuppressant medications (including ciclosporin, tacrolimus, and corticosteroids) without medical supervision, as it may theoretically counteract them.
Continuous long-term use: Most guidelines suggest not taking echinacea continuously for more than eight to twelve weeks, based on the theoretical concern that continuous immune stimulation could lead to tachyphylaxis (reduced response) or immune dysregulation. This recommendation is theoretical rather than robustly evidence-based, but cycling usage is prudent.
Pregnancy: There is insufficient safety data to recommend echinacea supplements during pregnancy, particularly in the first trimester. A German study found no increased miscarriage risk, but evidence is limited. Discuss with your midwife or GP.
Echinacea sits in an uncomfortable middle ground: the evidence is neither clearly positive nor clearly negative. Some preparations, used in some ways, may modestly reduce cold frequency or duration in some people. The overall magnitude of effect in meta-analyses is small. As a low-risk, reasonable-quality preparation used at the first sign of cold symptoms, echinacea is a defensible choice. As an expensive prophylactic taken daily all winter, the evidence does not strongly support the investment. The honest answer is: it might help a little, and it probably won't hurt.
For echinacea and immune-support supplements, shop at our partner
Shop at The Honey Pot →